ArticleAIDS (London, England)2026

A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks.

Zachary R Stephen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.